ASCO 2022 Conference Coverage


 

ASCO 2022 on the Addition of Carfilzomib as a Third Agent in Lenalidomide-Refractory MM: Switching From Doublet to Triplet

377 views
June 8, 2022
Comments 0
Login to view comments. Click here to Login